Clinical Trial Update: Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) [Phase 2]

View source ↗

Summary

AstraZeneca's Dato-DXd is being studied as a single agent and in combination with other anti-cancer drugs in an ongoing Phase 2 trial for advanced solid tumors,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Castration-resistant Prostate Cancer
• Colorectal Cancer
• Endometrial Cancer
• Gastric Cancer
• Ovarian Cancer
• Urothelial Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Endometrial Cancer, Gastric Cancer | Phase 2 | Status: RECRUITING